Literature DB >> 25572544

Preoperative ultrasound features as prognostic factors for patients with hepatocellular carcinoma.

Zhi-Yong Shen1, Gan-Lin Xia, Bing Hu, Yang-Gui Xie, Ming-Feng Wu.   

Abstract

PURPOSE: Ultrasound is the most common imaging tool used to scan the tumours of hepatic carcinoma patients. However, very few studies have been performed to evaluate ultrasound imaging features for predicting tumour prognosis. Therefore, the goal of the current study was to evaluate preoperative ultrasound characteristics as prognostic factors that could affect survival rate after liver resection for hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: A total of 104 HCC patients who underwent resection were retrospectively reviewed with regard to their clinical data, preoperative ultrasound characteristics, and survival rate. Preoperative ultrasound parameters included cirrhosis, tumour site, size, echo pattern, portal vein thrombosis, intra-tumour blood flow signal, peak systolic velocity (V max), and resistance index (RI). The Kaplan-Meier method was used to calculate survival. Pre-resection prognostic factors were assessed using univariate log-rank test and a multivariate Cox proportional hazards model.
RESULTS: The median survival was 37 months. The 1-, 3-, and 5-year disease-free survival (DFS) rates were 78.85, 53.85, and 26.92 %, respectively, and the overall survival (OS) rates at 1, 3, and 5 years were 85.58, 69.23, and 46.15 %, respectively. On univariate analysis, shorter survival was associated with mixed echo pattern, larger tumour size, portal vein thrombus, affluent flow signal, and higher V max. Application of the Cox multivariate proportional hazards model indicated that tumour size and blood flow signal in the tumours were independent prognostic factors.
CONCLUSIONS: The overall survival for HCC patients undergoing hepatic resection can be stratified on a sonographic basis of tumour size and intra-nodular vasculature. These prognostic factors may be useful to determine appropriate treatment for HCC patients.

Entities:  

Mesh:

Year:  2015        PMID: 25572544     DOI: 10.1007/s11547-014-0491-z

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  33 in total

Review 1.  Prognostic prediction and treatment strategy in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

Review 2.  Current strategy for staging and treatment: the BCLC update and future prospects.

Authors:  Alejandro Forner; María E Reig; Carlos Rodriguez de Lope; Jordi Bruix
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

3.  Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study.

Authors:  Zhi Li Wang; Ping Liang; Bao Wei Dong; Xiao Ling Yu; De Jiang Yu
Journal:  J Gastrointest Surg       Date:  2007-10-18       Impact factor: 3.452

Review 4.  New paradigms for the treatment of cancer: the role of anti-angiogenesis agents.

Authors:  J M Cherrington; L M Strawn; L K Shawver
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

5.  A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients.

Authors:  Stephanie Roessler; Hu-Liang Jia; Anuradha Budhu; Marshonna Forgues; Qing-Hai Ye; Ju-Seog Lee; Snorri S Thorgeirsson; Zhongtang Sun; Zhao-You Tang; Lun-Xiu Qin; Xin Wei Wang
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

6.  Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.

Authors:  Masatoshi Kudo; Hobyung Chung; Seiji Haji; Yukio Osaki; Hiroko Oka; Toshihito Seki; Hiroshi Kasugai; Yo Sasaki; Takashi Matsunaga
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

Review 7.  Local injection therapy for hepatocellular carcinoma.

Authors:  Xiao-Dong Lin; Li-Wu Lin
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2006-02

8.  The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes.

Authors:  King-Teh Lee; Yi-Wei Lu; Shen-Nien Wang; Hong-Yaw Chen; Shih-Chang Chuang; Wen-Tsan Chang; Hon-Yi Shi; Chen-Guo Ker; Herng-Chia Chiu
Journal:  J Surg Oncol       Date:  2009-05-01       Impact factor: 3.454

9.  Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma.

Authors:  Andrew X Zhu; Nagaraj S Holalkere; Alona Muzikansky; Kerry Horgan; Dushyant V Sahani
Journal:  Oncologist       Date:  2008-02

10.  Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes.

Authors:  Shimul A Shah; Sean P Cleary; Alice C Wei; Ilun Yang; Bryce R Taylor; Alan W Hemming; Bernard Langer; David R Grant; Paul D Greig; Steven Gallinger
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

View more
  1 in total

1.  Ultrasound cavitation enhanced chemotherapy: In vivo research and clinical application.

Authors:  Zhiyong Shen; Jingjing Shao; Jianquan Zhang; Weixing Qu
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.